首页> 外文期刊>癌と化学療法 >Assay for inhibitory activity of histone deacetylase
【24h】

Assay for inhibitory activity of histone deacetylase

机译:组蛋白脱乙酰酶的抑制活性的测定

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Recently, it has become clearer that abnormal epigenetics is profoundly involved in many human diseases. Histone acetylation is one of the important mechanisms by which epigenetics is controlled. Reversible histone acetylation, which occurs at conserved lysine residues clustered near the amino-terminus of core histones, mediates changes in nucleosome conformation and transcriptional activity. Acetylation and deacetylation are catalyzed by specific enzyme families, histone acetyltransferases (HATs) and deacetylases (HDACs), respectively. Since aberrant histone acetylation has been linked to malignant diseases in some cases, HDAC inhibitors bear great potential as new drugs due to their ability to modulate transcription and to induce differentiation and apoptosis. Some of the HDAC inhibitors are currently under clinical investigations. Therefore, HDAC has been considered as a molecular target for cancer therapy. We are providing a service for evaluating the HDAC inhibitory activity of compounds that are sent to the screening committee.
机译:最近,它变得更加清楚地,异常的表观遗传学是深刻的涉及许多人类疾病。组蛋白乙酰化是表观遗传学被控制的重要机制之一。在核心组蛋白氨基末端聚集在核心组末端的保守赖氨酸残基中发生的可逆组蛋白乙酰化,介导核心兼容性和转录活性的变化。乙酰化和脱乙酰化分别由特定酶家族,组蛋白乙酰转移酶(帽)和脱乙酰酶(HDACs)催化。由于在某些情况下,异常组蛋白乙酰化与恶性疾病联系起,由于它们的调节转录能力和诱导分化和凋亡,HDAC抑制剂具有巨大的潜力作为新药。一些HDAC抑制剂目前正在临床调查中。因此,HDAC被认为是癌症治疗的分子靶标。我们正在提供评估送到筛查委员会的化合物的HDAC抑制活性的服务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号